Printer Friendly

BRISTOL-MYERS SQUIBB INTRODUCES PRAVACHOL, A NEW CHOLESTEROL-LOWERING THERAPY

            BRISTOL-MYERS SQUIBB INTRODUCES PRAVACHOL,
               A NEW CHOLESTEROL-LOWERING THERAPY
    NEW YORK, Nov. 1 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced the introduction of Pravachol(R) (pravastatin sodium), an effective new drug to control elevated blood cholesterol levels.  The product will be available in the United States for physician prescribing in the very near future.
    Pravachol, a cholesterol synthesis inhibitor, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia when the response to a diet low in saturated fat and cholesterol alone is inadequate.
    Pravachol is available as 10 mg and 20 mg tablets.  Its convenient dosing, once-daily at bedtime with or without food, may contribute to increased patient compliance.
    Bristol-Myers Squibb Company is a diversified pharmaceutical company whose principal businesses are pharmaceuticals, nutritionals, consumer products and medical devices.  It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies and diagnostic agents.
    -0-                    11/1/91
    /NOTE TO EDITORS:  Bristol-Myers Squibb Company is planning a scientific briefing on Pravachol(R) (pravastatin sodium).  Media will be alerted to details shortly./
    /CONTACT:  Robert F. Laverty of Bristol-Myers Squibb, 609-921-5551/
    (BMY) CO:  Bristol-Myers Squibb Company ST:  New York IN:  MTC SU:  PDT GK -- NY010 -- 0070 11/01/91 08:38 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1991
Words:218
Previous Article:WESTERN GAS RESOURCES COMPLETES UNION TEXAS ACQUISITION
Next Article:WAL-MART TO OPEN 56 STORES IN ONE DAY
Topics:


Related Articles
BRISTOL-MYERS SQUIBB TO INTRODUCE PRAVACHOL, CHOLESTEROL-LOWERING AGENT
BRISTOL-MYERS SQUIBB INTRODUCES PRAVACHOL: A NEW CHOLESTEROL-LOWERING THERAPY
BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC
BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC
BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC (Product Announcement)
BRISTOL-MYERS SQUIBB STATEMENT REGARDING PUBLICATION OF KOBASHIGAWA STUDY IN SEPTEMBER 7 ISSUE OF NEW ENGLAND JOURNAL OF MEDICINE
FDA CLEARS PRAVACHOL(R) TO REDUCE RISK OF HEART ATTACK AND SLOW PROGRESSION OF ATHEROSCLEROSIS IN PATIENTS WITH ELEVATED CHOLESTEROL AND HEART DISEASE
FDA CLEARS PRAVACHOL(R) TO HELP PREVENT FIRST HEART ATTACK AND REDUCE DEATH FROM CARDIOVASCULAR DISEASE IN PATIENTS WITH ELEVATED CHOLESTEROL
Pravachol Reduces Risk of Recurrent Heart Attack and Death From Heart Disease According to Study Published in Latest Issue of the New England Journal...
New Evidence From Landmark Pravachol(R) (pravastatin sodium) Trials Demonstrates Significant Heart Attack Prevention Without Reducing Cholesterol to...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters